Fingolimod failure in progressive MS INFORMS future trials

被引：0
|
作者：
Andrew L. Smith
Jeffrey A. Cohen
机构：
[1] Mellen Center for Multiple Sclerosis Treatment and Research in the Neurological Institute,
[2] Cleveland Clinic,undefined
来源：
Nature Reviews Neurology | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fingolimod is approved for the treatment of relapsing–remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.
引用
收藏
页码：253 / 254
页数：1
相关论文
共 50 条
  • [21] Present and future treatment options in progressive MS
    Derfuss, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 7 - 7
  • [22] Lymphocyte counts and infection rates Long-term fingolimod treatment in primary progressive MS
    Fox, Edward J.
    Lublin, Fred D.
    Wolinsky, Jerry S.
    Cohen, Jeffrey A.
    Williams, Ian M.
    Meng, Xiangyi
    Ziehn, Marina
    Kolodny, Scott
    Cree, Bruce A. C.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (06):
  • [23] Diagnosis of pattern dystrophy in a case with multiple sclerosis (MS) on fingolimod (Gilenya) treatment and progressive dyschromatopsia
    Garnavou-Xirou, C.
    Xirou, T.
    Vasileias, D.
    Boutouri, E.
    Tsamis, D.
    Ragkousis, A.
    Gkizis, I.
    Anastasakis, A.
    Terzidou, C.
    Kabanarou, S.
    ACTA OPHTHALMOLOGICA, 2018, 96 : 44 - 45
  • [24] Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
    Lublin, Fred
    Miller, David H.
    Freedman, Mark S.
    Cree, Bruce A. C.
    Wolinsky, Jerry S.
    Weiner, Howard
    Lubetzki, Catherine
    Hartung, Hans-Peter
    Montalban, Xavier
    Uitdehaag, Bernard M. J.
    Merschhemke, Martin
    Li, Bingbing
    Putzki, Norman
    Liu, Fonda C.
    Haering, Dieter A.
    Kappos, Ludwig
    LANCET, 2016, 387 (10023): : 1075 - 1084
  • [25] Lessons from recent and ongoing treatment trials in progressive MS
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 127 - 127
  • [26] Fluid biomarker and electrophysiological outcome measures for progressive MS trials
    Barro, Christian
    Leocani, Letizia
    Leppert, David
    Comi, Giancarlo
    Kappos, Ludwig
    Kuhle, Jens
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (12) : 1600 - 1613
  • [27] Primary and secondary progressive MS subjects in clinical trials: Are they similar?
    Fox, Robert
    Ashokkumar, Akshata
    Coffey, Christopher
    Conwit, Robin
    Cudkowicz, Merit
    Ecklund, Dixie
    Gleason, Trevis
    Goodman, Andrew
    Klawiter, Eric
    Koepp, Maxine
    Matsuda, Kazuko
    McGovern, Michelle
    Naismith, Robert
    Natarajan, Sneha
    Thornell, Brenda
    Yankey, Jon
    NEUROLOGY, 2017, 88
  • [28] Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    de la Motte, Marine Boudot
    Louapre, Celine
    Bertrand, Anne
    Reach, Pauline
    Lubetzki, Catherine
    Papeix, Caroline
    Maillart, Elisabeth
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (04) : 614 - 616
  • [29] Past Informs Our Future
    Strecker, Mark
    AMERICAN HISTORY, 2016, 51 (02) : 6 - 6
  • [30] Fingolimod effect on disability progression in primary progressive multiple sclerosis patients with inflammatory activity: A post-hoc subgroup analysis of the INFORMS study
    Wolinsky, J. S.
    Cree, B. A. C.
    Freedman, M. S.
    Hartung, H. -P.
    Lublin, F.
    Miller, D. H.
    Montalban, X.
    Uitdehaag, B.
    Weiner, H.
    Lubetzki, C.
    Putzki, N.
    Li, B.
    Haring, D. A.
    Merschhemke, M.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 679 - 680
12345